You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSS Metastatic Colorectal Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low

Recruiting
  • NSCLC
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 28, 2022

Colorectal Tumors Trial in Xiamen (hypofractionation Radiotherapy, sintilimab, GM-CSF)

Recruiting
  • Colorectal Neoplasms
  • hypofractionation Radiotherapy
  • +3 more
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Mar 28, 2022

Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma Trial in

Active, not recruiting
  • Colorectal Adenocarcinoma
  • +7 more
  • Atlanta, Georgia
  • +2 more
May 6, 2022

Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma Trial in Trondheim, Lørenskog, Oslo

Not yet recruiting
  • Colorectal Adenocarcinoma
  • +2 more
  • Trondheim, Trondelag, Norway
  • +2 more
Aug 15, 2022

Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma

Not yet recruiting
  • Advanced Colorectal Adenocarcinoma
  • +5 more
  • Balstilimab
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston (CXCR1/2

Recruiting
  • Metastatic Colon Adenocarcinoma
  • +20 more
  • CXCR1/2 Inhibitor SX-682
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Refractory Metastatic Colorectal Cancer, pMMR, MSS Trial in United States (RP2, RP3, atezolizumab)

Not yet recruiting
  • Refractory Metastatic Colorectal Cancer
  • +2 more
  • RP2
  • +3 more
  • Los Angeles, California
  • +5 more
Feb 24, 2023

Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma Trial in Duarte

Active, not recruiting
  • Advanced Colon Adenocarcinoma
  • +24 more
  • Ipilimumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Aug 22, 2022

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +6 more
  • Balstilimab
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Nov 17, 2022

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer Trial (Sintilimab,

Not yet recruiting
  • Advanced Microsatellite Stable Colorectal Cancer
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Feb 3, 2021

Tislelizumab, Bevacizumab, Oxaliplatin Trial in Beijing (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Recruiting
  • Tislelizumab
  • +7 more
  • Beijing, China
    Lin Yang
Jul 21, 2023

Colorectal Cancer Trial (cadonilimab, irinotecan, Oxaliplatin)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 20, 2023

Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab + Envafolimab + mFOLFOXIRI
  • Cetuximab + mFOLFOX6/FOLFIRI
  • (no location specified)
Jul 24, 2023

Colorectal Cancer Trial (KN046, regorafenib)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Aug 2, 2023

Metastatic Colorectal Cancer, mCRC Trial in Guangzhou (Tislelizumab & Fruquintinib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • mCRC
  • Tislelizumab & Fruquintinib
  • Guangzhou, Guangdong, China
  • +1 more
Jan 25, 2023

Colorectal Tumors Trial (Envafolimab, recombinant human endostatin (endostatin))

Not yet recruiting
  • Colorectal Neoplasms
  • (no location specified)
Sep 19, 2022

CCR5, Microsatellite Stable, Metastatic Trial (700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at

Withdrawn
  • CCR5
  • +3 more
  • 700mg leronlimab weekly dose
  • +3 more
  • (no location specified)
Feb 15, 2023

Locally Advanced Colorectal Carcinoma Trial in Beijing (Cadonilimab, FOLFOX regimen)

Recruiting
  • Locally Advanced Colorectal Carcinoma
  • Beijing, Beijing, China
    Cancer Hospital/ National Cancer Center, Chinese Academy of Medi
Nov 23, 2023

New Patient Stratification Tools in MSS RAS mt mCRC

Completed
  • Advanced Colorectal Cancer
    • Heidelberg, Germany
    • +9 more
    Nov 25, 2022

    Metastatic Colorectal Cancer, MSS Trial in Heidelberg (Pembrolizumab, Maraviroc)

    Completed
    Has Results
    • Metastatic Colorectal Cancer
    • MSS
    • Heidelberg, Germany
      National Center for Tumor Diseases, University Hospital Heidelbe
    May 17, 2022

    NSCLC (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC) Trial in Worldwide (NZV930, PDR001,

    Terminated
    • Non-small Cell Lung Cancer (NSCLC)
    • +6 more
    • NZV930
    • +2 more
    • Tampa, Florida
    • +9 more
    Nov 2, 2022

    Metastatic Colorectal Cancer Trial in Providence (Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201

    Terminated
    Has Results
    • Metastatic Colorectal Cancer
    • Dose level 1 ONC201 625mg
    • +2 more
    • Providence, Rhode Island
      Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals
    May 25, 2022

    Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable Trial in Hangzhou (Tislelizumab, Irinotecan,

    Recruiting
    • Mismatch Repair-proficient
    • +2 more
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Dec 17, 2021

    Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis Trial in Shanghai (a combination therapy)

    Not yet recruiting
    • Advanced Rectal Cancer
    • +3 more
    • a combination therapy including tislelizumab
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Nov 9, 2022